GB002-3101 - Gossamer Bio - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
GB002, Inc.
Start Date
October 19, 2023
End Date
November 7, 2025
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
GB002, Inc.
Start Date
October 19, 2023
End Date
November 7, 2025